mRNA |
selumetinib:decitabine (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.061 |
0.07 |
mRNA |
lapatinib |
CCLE |
pan-cancer |
AAC |
-0.078 |
0.07 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.057 |
0.07 |
mRNA |
CI-976 |
CTRPv2 |
pan-cancer |
AAC |
0.068 |
0.07 |
mRNA |
MPS-1-IN-1 |
GDSC1000 |
pan-cancer |
AAC |
-0.056 |
0.07 |
mRNA |
THZ-2-102-1 |
GDSC1000 |
pan-cancer |
AAC |
-0.053 |
0.07 |
mRNA |
GDC-0449 |
FIMM |
pan-cancer |
AAC |
-0.3 |
0.08 |
mRNA |
IOX2 |
GDSC1000 |
pan-cancer |
AAC |
0.058 |
0.08 |
mRNA |
CEP-701 |
FIMM |
pan-cancer |
AAC |
-0.21 |
0.08 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.063 |
0.08 |